DORA PSI | Digital Object Repository at PSI

Export As:

Style

Style

Search Results 1 - 20 of 244

Sort

	Select Page
	First-in-human administration of [<sup>161</sup>Tb]Tb-SibuDAB and comparative dosimetry with standard [<sup>177</sup>Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study Chirindel, A., Nicolas, G. P., Westerbergh, F., McDougall, L., Schmid, D. E., Geistlich, S., … Schibli, R. (2025). First-in-human administration of [¹⁶¹Tb]Tb-SibuDAB and comparative dosimetry with standard [¹⁷⁷Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1628-1630. https://doi.org/10.1007/s00259-024-07009-w Detailed Record Published Version
	Preclinical investigation of [<sup>149</sup>Tb]Tb-DOTATATE and [<sup>149</sup>Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy Mapanao, A. K., Busslinger, S. D., Mehta, A., Kegler, K., Favaretto, C., Grundler, P. V., … Müller, C. (2025). Preclinical investigation of [¹⁴⁹Tb]Tb-DOTATATE and [¹⁴⁹Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1383-1398. https://doi.org/10.1007/s00259-024-07035-8 Detailed Record Published Version
	Biodistribution and dosimetry of [<sup>177</sup>Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer Ritt, P., Fernández, R., Soza-Ried, C., Nicolai, H., Amaral, H., Krieger, K., … Kramer, V. (2025). Biodistribution and dosimetry of [¹⁷⁷Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07102-8 Detailed Record Published Version
	Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form Wallimann, R. H., Mehta, A., Mapanao, A. K., Köster, U., Kneuer, R., Schindler, P., … Müller, C. (2025). Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1370-1382. https://doi.org/10.1007/s00259-024-07018-9 Detailed Record Published Version
	Site-specific modification of native IgGs with flexible drug-load Wehrmüller, J. E., Frei, J. C., Hechler, T., Kulke, M., Pahl, A., Béhé, M., … Spycher, P. R. (2025). Site-specific modification of native IgGs with flexible drug-load. ChemBioChem, 26(8), e202400511 (6 pp.). https://doi.org/10.1002/cbic.202400511 Detailed Record Published Version
	Terbium-149 production: a focus on yield and quality improvement towards preclinical application Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Busslinger, S. D., … van der Meulen, N. P. (2024). Terbium-149 production: a focus on yield and quality improvement towards preclinical application. Scientific Reports, 14(1), 3284 (12 pp.). https://doi.org/10.1038/s41598-024-53610-2 Detailed Record Published Version
	First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([<sup>161</sup>Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum Fricke, J., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., … Wild, D. (2024). First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([¹⁶¹Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. European Journal of Nuclear Medicine and Molecular Imaging, 51, 2517-2519. https://doi.org/10.1007/s00259-024-06641-w Detailed Record Published Version
	In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study Rottenburger, C., Hentschel, M., Fürstner, M., McDougall, L., Kottoros, D., Kaul, F., … Wild, D. (2024). In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [¹⁷⁷Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Research, 14(1), 37 (13 pp.). https://doi.org/10.1186/s13550-024-01101-w Detailed Record Published Version
	Targeting cancer stem cells with radioimmunotherapy: the case of the ovarian cancer stemness-associated biomarker L1CAM Todorov, T. Z., Schibli, R., Béhé, M., & Grünberg, J. (2024). Targeting cancer stem cells with radioimmunotherapy: the case of the ovarian cancer stemness-associated biomarker L1CAM. International Journal of Translational Medicine, 4(3), 463-485. https://doi.org/10.3390/ijtm4030031 Detailed Record Published Version
	Relaxed fibronectin: a potential novel target for imaging endometriotic lesions Trachsel, B., Imobersteg, S., Valpreda, G., Singer, G., Grabherr, R., Ormos, M., … Béhé, M. (2024). Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Research, 14(1), 17 (11 pp.). https://doi.org/10.1186/s13550-024-01070-0 Detailed Record Published Version
	Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder Vaccarin, C., Mapanao, A. K., Deberle, L. M., Becker, A. E., Borgna, F., Marzaro, G., … Müller, C. (2024). Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder. Cancers, 16(7), 1262 (13 pp.). https://doi.org/10.3390/cancers16071262 Detailed Record Published Version
	Liquid chromatography ICP-MS to assess the stability of <sup>175</sup>Lu- and <sup>nat</sup>Ga-based tumor-targeting agents towards the development of <sup>177</sup>Lu- and <sup>68</sup>Ga-labeled radiopharmaceuticals Wallimann, R. H., Hensinger, H., Müller, C., Schibli, R., Kneuer, R., & Schindler, P. (2024). Liquid chromatography ICP-MS to assess the stability of ¹⁷⁵Lu- and ^natGa-based tumor-targeting agents towards the development of ¹⁷⁷Lu- and ⁶⁸Ga-labeled radiopharmaceuticals. Pharmaceutics, 16(3), 299 (13 pp.). https://doi.org/10.3390/pharmaceutics16030299 Detailed Record Published Version
	A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides Beyer, D., Vaccarin, C., Deupi, X., Mapanao, A. K., Cohrs, S., Sozzi-Guo, F., … Müller, C. (2023). A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. EJNMMI Research, 13(1), 32 (14 pp.). https://doi.org/10.1186/s13550-023-00979-2 Detailed Record Published Version
	Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates Busslinger, S. D., Becker, A. E., Vaccarin, C., Deberle, L. M., Renz, M. L., Groehn, V., … Müller, C. (2023). Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates. Cancers, 15(17), 4259 (19 pp.). https://doi.org/10.3390/cancers15174259 Detailed Record Published Version
	<sup>161</sup>Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of <sup>161</sup>Tb into the clinic Favaretto, C., Grundler, P. V., Talip, Z., Landolt, S., Sepini, L., Köster, U., … van der Meulen, N. P. (2023). ¹⁶¹Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of ¹⁶¹Tb into the clinic. Journal of Nuclear Medicine, 64(7), 1138-1144. https://doi.org/10.2967/jnumed.122.265268 Detailed Record Published Version
	Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer Grzmil, M., Wiesmann, F., Schibli, R., & Behe, M. (2023). Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer. Cancers, 15(1), 17 (12 pp.). https://doi.org/10.3390/cancers15010017 Detailed Record Published Version
	Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers Pekeč, T., Venkatachalapathy, S., Shim, A. R., Paysan, D., Grzmil, M., Schibli, R., … Shivashankar, G. V. (2023). Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers. Scientific Reports, 13(1), 20662 (14 pp.). https://doi.org/10.1038/s41598-023-47287-2 Detailed Record Published Version
	Signaling network response to <em>α</em>-particle–targeted therapy with the <sup>225</sup>Ac-labeled minigastrin analog <sup>225</sup>Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors Qin, Y., Imobersteg, S., Frank, S., Blanc, A., Chiorazzo, T., Berger, P., … Grzmil, M. (2023). Signaling network response to α-particle–targeted therapy with the ²²⁵Ac-labeled minigastrin analog ²²⁵Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors. Journal of Nuclear Medicine, 64(6), 873-879. https://doi.org/10.2967/jnumed.122.264597 Detailed Record Published Version
	Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK Trachsel, B., Valpreda, G., Lutz, A., Schibli, R., Mu, L., & Béhé, M. (2023). Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. EJNMMI Radiopharmacy and Chemistry, 8(1), 21 (11 pp.). https://doi.org/10.1186/s41181-023-00206-2 Detailed Record Published Version
	Albumin-binding and conventional PSMA ligands in combination with <sup>161</sup>Tb: biodistribution, dosimetry, and preclinical therapy Tschan, V. J., Busslinger, S. D., Bernhardt, P., Grundler, P. V., Zeevaart, J. R., Köster, U., … Müller, C. (2023). Albumin-binding and conventional PSMA ligands in combination with ¹⁶¹Tb: biodistribution, dosimetry, and preclinical therapy. Journal of Nuclear Medicine, 64(10), 1625-1631. https://doi.org/10.2967/jnumed.123.265524 Detailed Record Published Version Accepted Version